T&R Biofab
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
T&R Biofab makes three-dimensional bioprinting systems and the materials that go with them, including bioink, a gel-like substance that keeps living cells alive during printing, to produce biodegradable scaffolds that help the body regenerate tissue.
Its products serve the regenerative medicine field, and it also supplies surgical products that apply the same biomaterial know-how to a range of surgical procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company runs three business lines, regenerative medicine, bio-surgical solutions, and cosmetics, with the cosmetics segment added as a nearer-term revenue source while longer-horizon programs such as organoids and cell therapies remain in development.
Summary is AI-generated and may contain errors · figures from DART filings
T&R Biofab in five facts
What does T&R Biofab do?
T&R Biofab makes three-dimensional bioprinting systems and the materials that go with them, including bioink, a gel-like substance that keeps living cells alive during printing, to produce biodegradable scaffolds that help the body regenerate tissue.
Where is T&R Biofab listed and in which sector?
T&R Biofab (Korean name: 티앤알바이오팹) trades under KRX code 246710 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is T&R Biofab?
Its market capitalisation was US$72.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were T&R Biofab's latest annual revenue and operating profit?
For fiscal year 2025, T&R Biofab reported revenue of US$20.4M, an operating loss of US$6.8M and a net loss of US$24.1M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 453.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Operating results (consolidated) (preliminary) (fair disclosure)
T&R Biofab filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$6.7M (+28.1% year on year).
Earnings · Oct 19 - Half-year report (2026.06)Aug 31
- Operating results (consolidated) (preliminary) (fair disclosure)
T&R Biofab filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$6.42M (+46% year on year).
Earnings · Jul 14 - Operating results (consolidated) (preliminary) (fair disclosure)
T&R Biofab filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$5.9M (+45.9% year on year).
Earnings · Apr 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
T&R Biofab reported consolidated results for FY2025: revenue of US$18.7M (+453.32% year on year), an operating loss of US$6.22M and a net loss of US$24.2M.
Earnings · Feb 25 - [Amended] Material event report (convertible bonds)Capital raise · Jan 29
- Operating results (consolidated) (preliminary) (fair disclosure)Earnings · Jan 21